Boehringer Ingelheim partners with 3T to develop cancer immunotherapies
German drugmaker Boehringer Ingelheim has partnered with US-based biotechnology company 3T Biosciences to discover and develop next-generation cancer immunotherapies. The latest partnership is the second research strategic collaboration